AI Finds Potential Drug Targets for Amyotrophic Lateral Sclerosis

2022-07-07T19:45:26+00:00

Scientists have identified several potential therapeutic targets for amyotrophic lateral sclerosis (ALS) using an artificial intelligence (AI)-powered target discovery engine to analyze dysregulated gene expression in large, publicly available ALS datasets.

AI Finds Potential Drug Targets for Amyotrophic Lateral Sclerosis2022-07-07T19:45:26+00:00

ALS Finding a Cure® funded Amylyx’s preclinical and early clinical work

2022-06-15T18:43:49+00:00

Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS Detailed data from the CENTAUR clinical trial were published in the New England Journal of Medicine,Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry

ALS Finding a Cure® funded Amylyx’s preclinical and early clinical work2022-06-15T18:43:49+00:00

ALS Finding a Cure® funded the SOD1 1/2 life work used in the Tofersen study

2022-06-15T18:44:53+00:00

Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease leading to loss of everyday functions and affecting approximately 2% of people with ALS

ALS Finding a Cure® funded the SOD1 1/2 life work used in the Tofersen study2022-06-15T18:44:53+00:00

ALS Finding a Cure® funded Eledon’s early clinical work for Tegoprubart when the drug was still with ALS TDI

2022-06-15T18:44:42+00:00

IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced topline results from a Phase 2a clinical trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS).1

ALS Finding a Cure® funded Eledon’s early clinical work for Tegoprubart when the drug was still with ALS TDI2022-06-15T18:44:42+00:00

ALS Association Supports Study of SARM1 Variants

2022-04-19T13:26:30+00:00

The ALS Association, in collaboration with ALS Finding a Cure, recently awarded $400,000 to support research into the role SARM1 gene mutations play in the development and progression of ALS, with the ultimate goal of using an improved understanding of SARM1 to develop new treatments. The research will be led by Dr. Jemeen Sreedharan at King’s College London and Dr. Michael Coleman at Cambridge University.

ALS Association Supports Study of SARM1 Variants2022-04-19T13:26:30+00:00

ALS Finding a Cure® and the ALS Association recent funding of four new grants

2022-04-06T14:40:35+00:00

Arrest ALS In collaboration with the ALS Association, we are pleased to announce the recent funding of four new grants designed to elucidate the biological linkages between key drivers of active axonal degeneration and ALS. ALS Finding a Cure® and the ALS Association are pleased to further scientific advances in this important area of research, which are sure to lead to future therapeutic insights. The four projects funded through the Arrest ALS collaboration include: Bloom/DiAntonio submission (Washington University in St. Louis): Pathological aggregation of the protein TDP-43 within motor neurons is seen in the majority of ALS cases (sporadic [...]

ALS Finding a Cure® and the ALS Association recent funding of four new grants2022-04-06T14:40:35+00:00

Healey Center for ALS in partnership with ALS Finding a Cure announces the 2021 ALS Scholars in Therapeutics Recipients

2022-04-06T14:10:45+00:00

Class of 2021 The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) in partnership with ALS Finding a Cure (ALSFAC) selected four recipients for their inaugural global two-year ALS Scholars in Therapeutics program. The program received an outstanding pool of global applications from 6 countries. This year’s selected recipients are Juliet Goldsmith, PhD of University of Pennsylvania, Matthew Anthony White, PhD of Kings College London, Brian Jude Joseph, PhD of Harvard University and Su Min Lim, PhD of Massachusetts General Hospital, Harvard Medical School. Learn about the ALS Scholars Program. [...]

Healey Center for ALS in partnership with ALS Finding a Cure announces the 2021 ALS Scholars in Therapeutics Recipients2022-04-06T14:10:45+00:00

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS

2022-04-06T14:40:49+00:00

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS Computational geneticist developed a blood test that could detect how fast muscle cells are dying, potentially aiding diagnosis. After a parent is diagnosed with an incurable disease, it’s natural to feel an urge to do anything possible to help. For some people, that could be advocacy, or household assistance, or tracking down the best available medical care. For Noah Zaitlen, Phd, associate professor of computational medicine and neurology at UCLA Health, it meant launching a research project to create a better diagnostic test for a debilitating neurological [...]

A loved one’s diagnosis moved this UCLA Health researcher to take on ALS2022-04-06T14:40:49+00:00
Go to Top